Recent Updates
Recently added Catalysts

Paradym CRT+ Physiological Diagnosis

Phase 2

Congestive Heart Failure | Unknown | Cardiovascular |LivaNova PLC|Last Updated: May 15, 2014

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

Double-BlindUNCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment520

FDA Designations

No designations recorded

Clinical trial landscape

Paradym CRT+ Physiological Diagnosis · 1 trial · 1 indication

Phase 2 1
NCT00957541Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) DeviceCongestive Heart Failure
COMPLETED520 Analytics
PHASE2COMPLETED
Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device
Congestive Heart FailureUnlock trial analytics

Study Endpoints

Primary Endpoints

Sensitivity of diagnostic feature in detecting heart failure events (using the device) in comparison to clinical heart failure events experienced by the patient (as classified by an independent committee).
Thirteen months
Mean number of false positives per patient per year.
Thirteen Months
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingTRIPLE
ModelSINGLE_GROUP
PurposeDIAGNOSTIC

Treatment Arms

ArmTypeDescription
CRT TherapyEXPERIMENTALAll patients will receive CRT therapy with the Physiological Diagnosis (PhD) feature enabled.

Interventions

NameTypeDescription
Paradym CRT + Physiological Diagnosis (PhD)DEVICEAll subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Subject eligible for implantation of a CRT-D device according to current available guidelines for cardiac resynchronization therapy * Subject has severe heart failure (NYHA Class III or IV) * Subject has experienced at least one heart failure event within six months prior to e...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Paradym CRT+ Physiological Diagnosis

What is Paradym CRT+ Physiological Diagnosis used for?

Paradym CRT+ Physiological Diagnosis is a cardiac resynchronization therapy device used for congestive heart failure. It is designed to deliver CRT and includes a diagnostic feature to evaluate the patient's condition. The device is intended for patients with heart failure who may benefit from resynchronization therapy.

Who makes Paradym CRT+ Physiological Diagnosis?

Paradym CRT+ Physiological Diagnosis is developed by LivaNova PLC, a company traded on the NASDAQ under the ticker LIVN. LivaNova is a medical technology company focused on cardiovascular and neuromodulation solutions. The device is part of their cardiac rhythm management portfolio.

What phase is Paradym CRT+ Physiological Diagnosis in?

Paradym CRT+ Physiological Diagnosis is in Phase 2 clinical development. It is an investigational device and has not been approved by the FDA. The Phase 2 trial has been completed, and the device is still in clinical development for the treatment of congestive heart failure.

What clinical trials is Paradym CRT+ Physiological Diagnosis in?

Paradym CRT+ Physiological Diagnosis has one completed Phase 2 clinical trial with the identifier NCT00957541. The trial, titled 'Evaluation of a Diagnostic Feature in a Cardiac Resynchronization Therapy (CRT) Device,' enrolled 520 participants in the United States. The study was double-blind and uncontrolled, and it included a biomarker selection component.

Is Paradym CRT+ Physiological Diagnosis the same as a standard CRT device?

Paradym CRT+ Physiological Diagnosis is a cardiac resynchronization therapy device with an added diagnostic feature. It is designed to evaluate physiological parameters in patients with congestive heart failure. The device is distinct from standard CRT devices due to this diagnostic capability, which may help in patient management.